GiovanellaL, VerburgFA. 2011. Ruling out 131I ablation in low-risk differentiated thyroid carcinoma basing on thyroglobulin measurement. Thyroid[Epub ahead of print].
2.
RosarioPW, XavierAC, CalsolariMR. 2011. Value of postoperative thyroglobulin and ultrasonography for the indication of ablation and 131I activity in patients with thyroid cancer and low risk of recurrence. Thyroid, 21:49–53.
3.
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules Differentiated Thyroid Cancer. CooperDS, DohertyGM, HaugenBR, KloosRT, LeeSL, MandelSJ, MazzaferriEL, McIverB, PaciniF, SchlumbergerM, ShermanSI, StewardDL, TuttleRM. 2009. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 19:1167–1214.
4.
NascimentoC, BorgetI, Al GhuzlanA, DeandreisD, ChamiL, TravagliJP, HartlD, LumbrosoJ, ChougnetC, LacroixL, BaudinE, SchlumbergerM, LeboulleuxS. 2011. Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr Relat Cancer, 18:R29–R40.
